Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

The Invesco Biotechnology & Genome ETF (PBE), a smart beta fund with $226.73 million in assets under management and a 0.58% expense ratio, offers concentrated exposure (99.8%) to the healthcare sector, specifically biotechnology and genome. As of October 3, 2025, PBE has delivered an 8.84% year-to-date return and 3.71% over the past year, but is highlighted as a high-risk option due to its concentrated portfolio of 32 holdings and a 20.59% three-year standard deviation. This positions PBE as a higher-risk, higher-cost option compared to larger, lower-expense market-cap weighted peers like SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB).

Analysis

The Invesco Biotechnology & Genome ETF (PBE) is a smart beta fund offering concentrated exposure to the healthcare sector, with assets under management of $226.73 million. Its strategy deviates from traditional market-cap weighting by employing a multi-factor model that evaluates companies on criteria including price and earnings momentum, quality, and value. The fund has delivered a year-to-date return of 8.84% and a 3.71% gain over the past year as of October 3, 2025. However, this performance is coupled with a high-risk profile, characterized by a three-year standard deviation of 20.59% and a concentrated portfolio of only 32 holdings, where the top ten positions account for 46.21% of total assets. PBE's annual operating expense of 0.58% is notably higher than larger, more liquid, market-cap weighted peers like the SPDR S&P Biotech ETF (XBI) at 0.35% and the iShares Biotechnology ETF (IBB) at 0.44%, positioning it as a higher-cost, higher-risk vehicle for investors seeking to outperform the broader biotech market through an active selection methodology.

Key Decisions for Investors

• Investors with a higher risk tolerance seeking active, factor-based exposure to the biotech sector could consider PBE for its potential to generate alpha, but should be aware of its higher expense ratio and concentration risk.
• Cost-conscious investors or those seeking broader, more diversified exposure to the biotechnology industry may find larger, lower-cost alternatives like XBI and IBB to be more suitable, given their market-cap weighting and superior liquidity.
• Given the fund's high concentration, with nearly half its assets in just ten stocks, holders of PBE should closely monitor the performance and news flow of its top holdings, such as Biogen and Vertex Pharmaceuticals, as they disproportionately impact the ETF's overall returns.